118 related articles for article (PubMed ID: 35529675)
1. Identification of BGN positive fibroblasts as a driving factor for colorectal cancer and development of its related prognostic model combined with machine learning.
Hu S; Xiao Q; Gao R; Qin J; Nie J; Chen Y; Lou J; Ding M; Pan Y; Wang S
BMC Cancer; 2024 Apr; 24(1):516. PubMed ID: 38654221
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
Cong L; Maishi N; Annan DA; Young MF; Morimoto H; Morimoto M; Nam JM; Hida Y; Hida K
Breast Cancer Res; 2021 May; 23(1):51. PubMed ID: 33966638
[TBL] [Abstract][Full Text] [Related]
3. Biglycan gene connects metabolic dysfunction with brain disorder.
Ying Z; Byun HR; Meng Q; Noble E; Zhang G; Yang X; Gomez-Pinilla F
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3679-3687. PubMed ID: 30291886
[TBL] [Abstract][Full Text] [Related]
4. Biglycan regulates bone development and regeneration.
Shainer R; Kram V; Kilts TM; Li L; Doyle AD; Shainer I; Martin D; Simon CG; Zeng-Brouwers J; Schaefer L; Young MF;
Front Physiol; 2023; 14():1119368. PubMed ID: 36875017
[TBL] [Abstract][Full Text] [Related]
5. Expanding the clinical spectrum of biglycan-related Meester-Loeys syndrome.
Meester JAN; Hebert A; Bastiaansen M; Rabaut L; Bastianen J; Boeckx N; Ashcroft K; Atwal PS; Benichou A; Billon C; Blankensteijn JD; Brennan P; Bucks SA; Campbell IM; Conrad S; Curtis SL; Dasouki M; Dent CL; Eden J; Goel H; Hartill V; Houweling AC; Isidor B; Jackson N; Koopman P; Korpioja A; Kraatari-Tiri M; Kuulavainen L; Lee K; Low KJ; Lu AC; McManus ML; Oakley SP; Oliver J; Organ NM; Overwater E; Revencu N; Trainer AH; Trivedi B; Turner CLS; Whittington R; Zankl A; Zentner D; Van Laer L; Verstraeten A; Loeys BL
NPJ Genom Med; 2024 Mar; 9(1):22. PubMed ID: 38531898
[TBL] [Abstract][Full Text] [Related]
6. BGN/FAP/STAT3 positive feedback loop mediated mutual interaction between tumor cells and mesothelial cells contributes to peritoneal metastasis of gastric cancer.
Wu H; Xiang Z; Huang G; He Q; Song J; Dou R; Yang C; Wang S; Xiong B
Int J Biol Sci; 2023; 19(2):465-483. PubMed ID: 36632455
[TBL] [Abstract][Full Text] [Related]
7. Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma.
Linder A; Westbom-Fremer S; Mateoiu C; Olsson Widjaja A; Österlund T; Veerla S; Ståhlberg A; Ulfenborg B; Hedenfalk I; Sundfeldt K
Hum Reprod; 2024 May; 39(5):1141-1154. PubMed ID: 38459814
[TBL] [Abstract][Full Text] [Related]
8. Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma.
Schäfer H; Subbarayan K; Massa C; Vaxevanis C; Mueller A; Seliger B
J Transl Med; 2023 Sep; 21(1):643. PubMed ID: 37730606
[TBL] [Abstract][Full Text] [Related]
9. The Landscape of Small Leucine-Rich Proteoglycan Impact on Cancer Pathogenesis with a Focus on Biglycan and Lumican.
Berdiaki A; Giatagana EM; Tzanakakis G; Nikitovic D
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509212
[TBL] [Abstract][Full Text] [Related]
10. Biglycan potentially regulates angiogenesis during fracture repair by altering expression and function of endostatin.
Myren M; Kirby DJ; Noonan ML; Maeda A; Owens RT; Ricard-Blum S; Kram V; Kilts TM; Young MF
Matrix Biol; 2016; 52-54():141-150. PubMed ID: 27072616
[TBL] [Abstract][Full Text] [Related]
11. The role of biglycan in the healthy and thoracic aneurysmal aorta.
Meester JAN; De Kinderen P; Verstraeten A; Loeys BL
Am J Physiol Cell Physiol; 2022 Jun; 322(6):C1214-C1222. PubMed ID: 35476501
[TBL] [Abstract][Full Text] [Related]
12. Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.
Subbarayan K; Massa C; Leisz S; Steven A; Bethmann D; Biehl K; Wickenhauser C; Seliger B
Oncoimmunology; 2022; 11(1):2069214. PubMed ID: 35529675
[TBL] [Abstract][Full Text] [Related]
13. Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.
Subbarayan K; Leisz S; Wickenhauser C; Bethmann D; Massa C; Steven A; Seliger B
Oncoimmunology; 2018; 7(4):e1373233. PubMed ID: 29632715
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties.
Recktenwald CV; Leisz S; Steven A; Mimura K; Müller A; Wulfänger J; Kiessling R; Seliger B
J Biol Chem; 2012 Jul; 287(29):24320-9. PubMed ID: 22582394
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of the extracellular matrix component Biglycan regulated by Hedgehog signalling promotes colorectal cancer cell proliferation.
Zeng S; Zhou F; Wang Y; Zhai Z; Xu L; Wang H; Chen X; Luo S; Cheng M
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):243-251. PubMed ID: 35130618
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
